Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Glucocorticosteroid and chemotherapy medicament carried by anticancer sustained-release agent

A technology of glucocorticoids and corticosteroids, which is applied in drug delivery, drug combination, antineoplastic drugs, etc., can solve the problems of increased resistance to anticancer drugs, limitation of effective drug diffusion, and obstacles to tumor chemotherapy, so as to improve interstitial Liquid conductivity, inhibiting the formation of new blood vessels, facilitating penetration and diffusion

Inactive Publication Date: 2009-08-12
SHANDONG LANJIN PHARMA
View PDF11 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The above factors greatly limit the effective diffusion of drugs into solid tumors and tumors, thus constituting the main obstacle to tumor chemotherapy.
[0007] Not only that, the blood vessels in the tumor interstitium are not sensitive to conventional chemotherapy drugs, which often lead to the enhancement of tumor cell resistance to anticancer drugs, local chemotherapy is often complicated by local edema, and the result is treatment failure

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0147] Put 80 parts of polyphenylpropane (p-CPP: sebacic acid (SA) at 20:80) copolymer into a container, add 100 ml of dichloromethane, dissolve and mix well, then add 10 parts of dexamethasone and 10 parts of 7-hydroxy-staurosporine, re-shake and spray-dry to prepare an injection containing 10% dexamethasone and 10% 7-hydroxy-staurosporine Use microspheres. Then suspend the microspheres in physiological saline containing 15% mannitol to prepare the corresponding suspension-type sustained-release injection. The drug release time of the slow-release injection in the physiological saline in vitro is 30-55 days, and the drug release time in the mouse subcutaneous is about 30 days.

Embodiment 2

[0149] The method steps for processing into sustained-release injections are the same as in Example 1, but the difference is that polyphenylene is 50:50; the anti-cancer active ingredients and their weight percentages are: 0.1-10% prednisolone, Methylprednisolone, dexamethasone, betamethasone, triamcinolone, or triamcinolone acetonide with 1-40% of 7-hydroxy-staurosporine, 7-O-alkyl-staurosporine , β-methoxystaurosporine, alkylphosphocholine or a combination of hexadecylphosphocholine.

Embodiment 3

[0151] 80 mg of polylactic acid (PLA) with a peak molecular weight of 20,000-40,000 is put into a container, 100 ml of methylene chloride is added, after dissolving and mixing, 5 mg of prednisolone and 15 mg of 7-ethyl-10-hydroxycamptothecin are added, Shake again and dry in vacuo to remove the organic solvent. The dried drug-containing solid composition is frozen and pulverized to make micropowder containing 5% prednisolone and 15% 7-ethyl-10-hydroxycamptothecin, and then suspended in 1.5% sodium carboxymethylcellulose In physiological saline, the corresponding suspension-type sustained-release injection was prepared. The drug release time of the slow-release injection in physiological saline in vitro is 20-35 days, and the drug release time in mice subcutaneous is about 35-50 days.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Viscosityaaaaaaaaaa
Login to View More

Abstract

The invention provides an anti-cancer sustained-release agent co-carrying glucocorticoid and chemotherapeutic drugs and belongs to sustained-release injections. The anti-cancer sustained-release agent comprises sustained-release microspheres and a solvent, wherein, the sustained-release microspheres comprise anti-cancer active components and sustained-release auxiliary materials; and the solvent is a particular solvent containing a suspending agent. The glucocorticoid is selected from prednisolone, methylprednisolone, dexamethasone, betemethasone, triamcinolone acetonide or triamcinolone acetonide; the chemotherapeutic drugs are selected from phosphoinositide 3-kinase inhibitor, pyrimidine analogues and the like; the sustained-release auxiliary materials are biocompatible high-polymers, such as polylactic acid and the copolymers thereof, polyethylene glycol, carboxyl-terminated polylactic acid copolymers, polyfatty acid dimer-sebacic acid copolymers, poly(erucic acid dimer-sebacic acid), poly(fumaric-co-sebacic acid), polifeprosan and the like; and the suspending agent with the viscosity being 100cp to 3,000cp (at the temperature of 20 to 30 DEG C) is selected from sodium carboxymethyl cellulose and the like. The anti-cancer active components and the sustained-release microspheres can further be prepared into sustained-release implants which can effectively inhibit the growth of tumors, alleviate edema and improve the curative effects of radiotherapy and chemotherapy by intra-tumor or peri-tumor injection or placement.

Description

(1) Technical field [0001] The invention relates to an anticancer slow-release agent containing glucocorticoid and chemotherapy drugs, belonging to the technical field of medicines. Specifically, the invention provides a sustained-release injection and a sustained-release implant containing glucocorticoid. The anti-cancer slow-release agent can effectively inhibit or destroy the solid tumor stroma and tumor blood vessels, and can inhibit tumor angiogenesis, effectively reduce the tension in the tumor, interstitial pressure, and interstitial viscosity, thereby improving its interstitial fluid conduction. It is conducive to the effective diffusion of drugs into solid tumors and tumors, and can also increase drug sensitivity. (2) Background technology [0002] Traditional chemotherapy is not selective, and it is difficult to form an effective drug concentration or therapeutic dose locally in the tumor. The effect is poor and the toxicity is high. Simply increasing the drug or ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/00A61K9/10A61K45/06A61K47/30A61P35/00
Inventor 孔庆忠邹会凤刘恩祥苏红清
Owner SHANDONG LANJIN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com